Through a glass darkly: can we improve clarity about mechanism and aims of medications in drug and alcohol treatments?

Abstract

Get full access to this article

View all access options for this article.

References

Boeijinga

Parot

Soufflet

(2004) Pharmacodynamic effects of acamprosate on markers of cerebral function in alcohol-dependent subjects administered as pretreatment and during alcohol abstinence. Neuropsychobiology 50: 71–77.

Chick

Lehert

Landron

(2003) Does acamprosate improve reduction of drinking as well as aiding abstinence? J Psychopharmacol 17: 387–392.

Chick

Nutt

(2011) Substitution therapy for alcoholism: time for a reappraisal? J Psychopharmacol 26: 204–211.

Crunelle

Miller

Booij

van den Brink

(2010) The nicotinic acetylcholine receptor partial agonist varenicline and the treatment of drug dependence: a review. Eur Neuropsychopharmacol 20: 69–79.

Franklin

Harper

Kampman

Kildea-McCrea

Jens

Lynch

O’Brien

Childress

(2009) The GABA B agonist baclofen reduces cigarette consumption in a preliminary double-blind placebo-controlled smoking reduction study. Drug Alcohol Depend 103: 30–36.

Grant

Kim

Hartman

(2008) A double-blind, placebo-controlled study of the opiate antagonist naltrexone in the treatment of pathological gambling urges. J Clin Psychiatry 69: 783–789.

Johnson

Rosenthal

Capece

Topiramate for Alcoholism Advisory Board; Topiramate for Alcoholism Study Group (2007) Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA 298: 1641–1651.

Kranzler

Tennen

Armeli

Chan

Covault

Arias

. (2009) Targeted naltrexone for problem drinkers. J Clin Psychopharmacol 29: 350–357.

Karhuvaara

Simojoki

Virta

Rosberg

Löyttyniemi

Nurminen

. (2007) Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study. Alcohol Clin Exp Res 31: 1179–1187.

10.

Leggio

Garbutt

Addolorato

(2010) Effectiveness and safety of baclofen in the treatment of alcohol dependent patients. CNS Neurol Disord Drug Targets 9: 33–44.

11.

Lingford-Hughes

Welch

Nutt

British Association for Psychopharmacology (2004) Evidence-based guidelines for the pharmacological management of substance misuse, addiction and comorbidity: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 18: 293–335.

12.

Lingford-Hughes

Watson

Kalk

Reid

(2010) Neuropharmacology of addiction and how it informs treatment. Br Med Bull 96: 93–110.

13.

Mann

Kiefer

Spanagel

Littleton

(2008) Acamprosate: recent findings and future research directions. Alcohol Clin Exp Res 32: 1105–1110.

14.

NICE (2011) Alcohol use disorders: diagnosis, assessment and management of harmful drinking and alcohol dependence NICE clinical guideline 115. London: National Institute for Health and Clinical Excellence.

15.

Nutt

(2003) Death and dependence: current controversies over the selective serotonin reuptake inhibitors. J Psychopharmacol 17: 355–364.

16.

Nutt

(2010) Antagonist-agonist combinations as therapies for heroin addiction: back to the future? J Psychopharmacol 24: 141–145.

17.

O’Malley

Jaffe

Chang

. (1992) Naltrexone and coping skills therapy for alcohol dependence. Arch Gen Psychiatry 49: 881–7.

18.

Rösner

Leucht

Lehert

Soyka

(2008) Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes. J Psychopharmacol 22: 11–23.

19.

Volpicelli

Alterman

Hayashida

. (1992) Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 49: 876–80.